84results about How to "Antitumor effect is obvious" patented technology

The invention discloses a preparation method of magnetic induction hyperthermia embolism microspheres. The preparation method comprises the following steps of by taking a dissolved matter obtained bydissolving biodegradable high molecular polymers with low transition temperature and super paramagnetic Fe3O4 nano-particles into dichloromethane as an oil phase, Span 80 as a surfactant and an aqueous solution dissolved with polyvinyl alcohol (PVA) as an internal water phase, dropwise adding a water phase in the oil phase under the conditions with low temperature and high shearing to form primaryemulsion; placing the primary emulsion in a membrane emulsification instrument for membrane emulsification under the low temperature condition; forming multiple emulsion in a continuous phase of an external water phase PVA after the primary emulsion permeates a membrane, and performing low-temperature solidification to obtain the magnetic induction hyperthermia embolism microspheres which meet the demand for clinic size. The obtained microspheres are arbitrarily adjustable in size in a range from 100 microns to 1000 microns, can realize rabbit orthotopic liver cancer model embolism hyperthermia under guidance of iconography and have potential application in the interventional hyperthermia field of orthotopic tumors.

The invention relates to application of protosappanin B, in particular to application of a 0.2 to 2.4 percent protosappanin B solution in preparation of bladder cancer resistant perfusion fluid. For filling up the research blank of the protosappanin B at home and abroad, the invention provides new application of the protosappanin B. Human bladder cancer cell strains T24 or mouse bladder cancer cell strains BTT are inoculated to mouse bodies to form bladder cancer, and the mice are grouped and respectively subjected to experiments with injection water, mitomycin and the protosappanin B; experiment results show that the lives of the mice injected with the mitomycin and the protosappanin B are prolonged, the tumor weight is reduced, and a tumor inhibiting effect is achieved; and the protosappanin B has a remarkable bladder cancer inhibiting effect, and can be widely applied to preparation of the bladder cancer resistant perfusion fluid.

The invention discloses a preparation method and an application of A-D-A type organic molecule/amphiphilic polymer composite nanoparticles, and relates to an application of organic molecules in the field of biological medicines. A non-fullerene receptor with an A-D-A structure, widely used in the organic photovoltaic field, has the unique advantages of easiness in structure adjustment, strong near-infrared light absorption capacity and low fluorescence quantum efficiency, and has the huge potential of being used as a photosensitizer for photo-thermal/photodynamic combined treatment. The organic molecule with the A-D-A structure is coated with an amphiphilic macromolecule to form the water-soluble composite nanoparticles, the composite nanoparticles show a high photothermal conversion efficiency and a high reactive oxygen generation capacity under irradiation of near-infrared laser with a certain wavelength, and mouse in-vivo experiments show that the water-soluble composite nanoparticles have an obvious inhibition effect on tumors. Therefore, the composite nanoparticles have great practical prospects and social values in the field of novel tumor treatment.

The invention provides an anti-tumor tetravalent platinum complex with an anti-drug resistance function and a preparation method thereof. The structural formula of the compound is shown as a formula Ior a formula II, and the compound is one of the following structures: the compound has excellent cytotoxic activity to tumor cells, especially to cisplatin-resistant tumor cells, and shows excellenttumor inhibition effect and relatively low toxicity in vivo.

The invention belongs to the technical field of genetic engineering antibodies, and particularly relates to a preparation method and application of CD24 antibody fusion protein. The preparation method includes that genetic engineering technology is utilized to connect CD24 single-strand antibody rG7S with MICA extracellular 1-3 zones through G4S flexible peptide, and a mammal eukaryotic expression system stably expresses rG7S-MICA; the CD24 antibody fusion protein rG7S-MICA can be combined with CD24 molecules on the surface of tumor cells and an activated receptor NKG2D on the surface of NK cells at the same time, and can remodel immunological surveillance effect, on CD24+tumor cells, of NK cells induced through an NKG2D path to finally achieve the objective of activating a body autoimmune system to effectively kill the CD24+tumor cells.

The invention discloses a method for preparing for tumour formingblood vessel peculiarity binding polypeptide and the admixture protein of human-5. The tumour formingblood vessel peculiarity binding polypeptid-CNGRCVSGCAGRC can separately combine with the tumour formingblood vessel endothelium cell surface high effect expressed aminopeptidase N (CD13). It establishes tumour formingblood vessel peculiarity binding polypeptide and the admixture protein of human-5 and obtains the high effect express in bacillus coli. It also discloses a method for preparing for human Tum-5. The Tum-5 is formed by the 54-132 bits amino acid near the N end of the Tumstatin, which is the function structure area of the Tumstatin anti-vascularization.

The invention relates to a bacterial outer membrane vesicle, a nano vaccine containing the bacterial outer membrane vesicle as well as a preparation method and application thereof. The bacterial outermembrane vesicle contains molecular gluewater protein SpyCatcher and/or SnoopCatcher, the tumor vaccine comprises the bacterial outer membrane vesicle and an antigen connected with the bacterial outer membrane vesicle in the form of an isopeptide bond, and the antigen carries SpyTag and/or SnoopTag. According to the invention, the bacterial outer membrane vesicle containing molecular gluewater protein SpyCatcher and SnoopCatcher is used as a tumor vaccine platform and is connected with the antigen carrying SpyTag and/or SnoopTag to obtain the tumor vaccine, and the tumor vaccine can effectively activate an organism to generate innate immunity and realize specific killing of a plurality of antigens at the same time. According to the method, personalized tumor vaccines for tumors from different sources can be rapidly obtained.

The invention discloses an oncolytic virus and neoantigen combined tumor vaccine and a preparation method thereof. The combined vaccine can be implemented through the following two ways: in the firstway, an immune response reaction generated from an oncolytic virus reagent is used for improving the efficiency for phagocytizing a polypeptide reagent by an antigen presenting cell, increasing the number of T cells which can specifically identify a neoantigen and improving the tumor invasion performance of the T cells so as to enhance the anti-cancer curative effect; and in the second way, a genecoding a tumor neoantigen is inserted into an oncolytic virus vector to massively express the tumor neoantigen, and is combined with the tumor killing performance of the oncolytic virus to further enhance the immune response reaction of a tumor focus local part and improve the invasion degree of the killing type T cell in a tumor tissue, so that the local part can generate an immune response reaction, and generation of an effector cell is stimulated to achieve an anti-cancer effect. Experiment comparison discovers that the first combined vaccine and the second combined vaccine have an excellent tumor inhibition effect, and the second combined vaccine has a remarkable tumor inhibition effect.

The invention provides a host factor hPRDX5 with an anti-tumor effect, an encoding gene and application of the host factor, and belongs to the technical field of cancer treatment. The host factor hPRDX5 is a single protein component, has the advantages of good preparation repeatability and controllable quality, does not generate immunogenicity when applied to humans and has incomparable advantagescompared with ACBPs. The host gene hPRDX5 can significantly inhibit growth of in-situ pancreatic cancer tumors, and by studying the adjustment and control effects of the hPRDX5 on CD4, CD8, NKT and MDSCs cells in a tumor immunity micro-environment of a pancreatic cancer mouse, it is discovered that compared with a control group, the proportion of CD4+T, CD8+T and NKT cells in pancreatic tumor tissue is significantly increased after treatment by the hPRDX5. Therefore through application of the host factor hPRDX5 in preparation of anti-tumor drugs, the tumor load can be effectively reduced, andthe period of survival with tumors is prolonged.

The invention provides a multi-functional tumor-targeted nanometer preparation and a construction method and application in treating tumors thereof. By means of the nanometer preparation, the tumors can be treated by using the RNA interference technology cooperating with the photothermal therapy, the RNA interference technology and the photothermal therapy cooperatively inhabit the growth of the tumors, and a better tumor treatment effect is achieved. The nanometer preparation comprises effector molecules, a nanometer material and targeting molecules, wherein the effector molecules comprise nucleic acid molecules for RNA interference; a photothermal effect is formed by the nanometer material; the targeting molecules are used for delivering the particular cells which the nanometer preparation arrives at. The nanometer preparation process is mild in condition, the cost is low, and the nanometer preparation is good in biocompatibility, targeting ability, siRNA loading and unloading capacity, serum protection effect and tumor-suppression effect. The industrialization implementating prospect of the nanometer preparation is wide, and the corresponding treatment method is a new potentialtumor treatment thought.

The invention belongs to the chemical industry field and the medicine field, and relates to an application of magnolol in preparation of antitumor drugs. The invention provides the application of magnolol in preparation of antitumor drugs, and the tumor cells comprise liver cancer cells, and cervical cancer cells. The magnolol belongs to a natural product, has little toxic and side effect, high bioavailability, and stable properties, and has clinical application value. The micromolecular compound of the invention can be developed as a new antitumor drug or its auxiliary component, has obvious tumor suppression effect, is green and environment-friendly, and provides a new approach and means for treating and curing tumors.

The invention belongs to the technical field of biological medicines, and particularly relates to application of SEMA4C in preparation of antitumor drugs. Based on research on breast cancer, SEMA4C with high breast cancer tissue specificity expression is found, and the SEMA4C with high expression participates in tumor metastasis invasion and tumor proliferation related to lymphatic vessel formation of breast cancer. However, the development of neutralizing antibodies in the aspects of immunoregulation, participation in anti-tumor reaction and medicines has not been studied and reported. According to the application, the interaction mode of SEMA4C and T cells is proved, a neutralizing antibody capable of blocking combination of SEMA4C and T cells is screened out, and an in-vitro co-culture experiment result shows that anti-SEMA4C can recover chemotactic and anti-tumor functions of the T cells; and in-vivo experiments find that anti-SEMA4C can significantly inhibit tumor growth, and the tumor inhibition effect is obviously better than that of anti-PD-1, which indicates that the SEMA4C neutralizing antibody has great potential in the anti-tumor aspect.

The invention discloses a novel integrin blocker/GnRH agonist fusion protein and a preparation method thereof, and application of the protein in anti-tumor.

The invention belongs to the field of tumor treatment, and discloses an antibody fusion protein, a preparation method thereof and the application thereof in tumor resistance. The antibody fusion protein specifically comprises an anti-HER2 monoclonal antibody IgG and a D2 domain of VEGFR1, and the D2 domain of VEGFR1 is connected to the C-terminus of an IgG heavy chain through a peptide connector L. The antibody fusion protein can block HER2 and VEGFR2 signal channels at the same time, has a tumor proliferation inhibition effect superior to that of the monoclonal antibody, provides a candidatedrug with a better treatment effect for anti-tumor treatment, and has a wide application prospect in treatment of tumor diseases.

The invention belongs to the technical field of molecular diagnosis, and particularly relates to lncRNA LLNLR-299G3.1 related to esophageal squamous cell carcinoma (ESCC) and an application thereof. According to the invention, the lncRNA (LLNLR-299 G3.1) with obvious cancer promoting activity is proved by experimental analysis, so that a new target point is provided for a new scheme of individualized accurate treatment of ESCC. Expression of the lncRNA in plasma exudates of ESCC patients and in ESCC cells is significantly higher than expression in plasma exudates of healthy people and in normal esophageal epithelial cells respectively. The research results show that the lncRNA has obvious capability of promoting tumor activity of ESCC cells, and through inhibition of expression of the lncRNA in cells and a nude mouse transplanted tumor model, proliferation and migration capability of ESCC cells can be obviously inhibited.

The invention discloses a cryptolepis sinensis zinc (II) complex with in-vitro and in-vivo high activity, belongs to the field of medicines, and mainly solves the technical problem of lung cancer cis-platinum drug resistance in the prior art, and the chemical formula of the cryptolepis sinensis zinc (II) complex is [Zn (BQTC)] Cl2. A synthetic method of the compound specifically comprises the following steps: reacting 1, 4, 7-tritert-butyloxycarbonyl-1, 4, 7, 10-tetraazacyclododecane, 7-hydroxyheptanoic acid, 1-ethyl-3 (3-dimethyl propylamine) carbodiimide and pyridine to obtain a compound 1; reacting the compound 1, cryptolepine derivative BQ and NaH to generate a yellow compound 2; adding an HCl/dioxane solution and CH2Cl2 into the compound 2, and reacting to generate a yellow ligand BQTC; and carrying out coordination reaction on the ligand BQTC and zinc chloride to obtain the cryptolepis sinensis zinc (II) complex. The cryptolepine zinc complex inhibits growth of a human lung adenocarcinoma-resistant cis-platinum strain A549R in a targeted manner, in-vivo tumor inhibition experiments show that the cryptolepine zinc complex Zn (BQTC) has a good tumor inhibition effect on a nude mouse model bearing the human lung adenocarcinoma-resistant cis-platinum strain A549R, the inhibition rate reaches up to 55.9%, and the cryptolepine zinc complex Zn (BQTC) has potential medicinal value and is expected to be used for preparing various antitumor drugs.

The invention relates to the fields of organic synthesis and medicine chemistry, in particular to a compound of a platinum derivative and sodium hyaluronate and application thereof. The platinum derivative and the sodium hyaluronate are subjected to combined administration, and can be applied for preparing an anti-neoplastic medicine, pharmacology experiments show that the anti-neoplastic medicinehas obvious anti-neoplastic effects on different cancer cells, specifically, the platinum derivative and sodium hyaluronate combined compound has the obvious anti-neoplastic effects, the anti-neoplastic effects are relative to the kind of the platinum derivative, and combination of the two medicines is in a dosage range; the medicine combined compound can effectively relieve toxic and side effects which are brought by individual administration of the platinum derivative; the medicine combined compound has potential development values for the novel efficient anti-tolerance anti-neoplastic medicine with low toxic and side effects.

The invention discloses a preparation method and application of a self-oxygen-carrying photo-thermal preparation/anthracene endoperoxide/polymer composite nanoparticle, and relates to application of organic molecules in the field of biological medicines. Photodynamic/photo-thermal combined treatment is broadly concerned due to the characteristics of convenience in operation, no invasion, local selectivity, small drug resistance, small side effect and the like. However, photodynamic treatment has the dependence on the concentration of tumor tissue oxygen, and the treatment efficiency is limited. According to the preparation method, a self-oxygen-carrying photosensitizer anthracene endoperoxide is selected and used with a photo-thermal preparation, and two types of organic molecules are coated with amphiphilic polymers to form water-soluble composite nanoparticles, and the water-soluble composite nanoparticles represent high photo-thermal conversion efficiency, high active oxygen yield and obvious tumor growth inhibition effect after being irradiated by near-infrared light (880nm). Therefore, the preparation method has an important practical prospect and social value in the field ofnovel tumor treatment.

The invention discloses an anti-cholangiocarcinoma medicine composition and an application thereof. The medicine composition comprises active components and pharmaceutically acceptable auxiliary materials, wherein the active components comprise capecitabine and 2-lactoyl aminobenzoic acid. By virtue of tests, according to the anti-cholangiocarcinoma medicine composition disclosed by the invention, the effects of cooperatively enhancing the anti-cancer cell proliferation can be achieved by combining 2-lactoyl aminobenzoic acid and capecitabine, so that the treatment purpose of resisting cholangiocarcinoma can be achieved more beneficially.

The invention discloses a preparation method and application of a double-ligand modified liver cancer targeted liposome. The preparation method comprises the following steps: dissolving soybean lecithin, cholesterol, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and distearoyl phosphatidyl ethanolamine-polyethylene glycol 1000 connected with TAT peptide with a proper amount of chloroform; carrying out reduced-pressure rotary evaporation on the dissolved solution to form a uniform hyaluronic membrane, and then carrying out vacuum drying; adding a proper amount of distearoyl phosphatidyl ethanolamine-polyethylene glycol 3400 which is connected with the SP94 peptide into the dried hyaluronic membrane; according to the invention, adriamycin is used as a model drug and is entrapped in the SP94 and TAT co-modified liposome, and after the liposome reaches the interior of liver cancer cells through a targeting effect, adriamycin is released, so that a good tumor inhibition effect is achieved, and the side effect of the drug is reduced; the liver cancer targeting ability and cytotoxicity of the constructed SP94 and TAT co-modified adriamycin liposome are evaluated, and a new strategy is provided for enhancing liver cancer drug delivery.

The invention provides a preparation method of an MXene-based drug delivery system integrating CT radiography, photo-thermal therapy and drug sustained release. The preparation method specifically comprises the following steps: preparing an MAX-phase ceramic precursor by an excessive Al method; doping elements by a molten salt method and synthesizing an MXene material; a drug is loaded on the MXene material, and due to the photo-thermal property of the MXene material, a dual-combined treatment method of simultaneously carrying out drug treatment and photo-thermal treatment can be realized. The MXene material prepared by the invention has an antioxidant property and is easy to store, the doped elements can enhance the CT development effect, an individualized precise treatment mode of preoperative diagnosis, intraoperative tracking and postoperative evaluation of diseases can be realized at the same time, and wounds caused by examination and treatment to patients are reduced.